On Mar. 22, 2021, CureVac announced plans to expand and further specify the protocols of its ongoing late-stage clinical trials with CVnCoV, its COVID-19 vaccine candidate. Rapid distribution of new virus variants in the countries where the study was conducted supported the need for further analysis specification for the anticipated case-driven interim analysis.